CM-24 is under clinical development by Purple Biotech and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition success rate ...

CM-24 is under clinical development by Purple Biotech and currently in Phase I for Non-Small Cell Lung Cancer.

Purple Biotech has identified a new serum biomarker, CEACAM1, which may significantly enhance the efficacy of their oncology therapeutic candidate, CM24, for treating metastatic pancreatic cancer.

Shares of Purple Biotech Ltd (NASDAQ:PPBT – Get Free Report) traded down 2.1% on Thursday . The company traded as low as $4.28 and last traded at $4.59. 140,696 shares changed hands during trading, a ...

Our team published hundreds of articles over the course of the year, but these were some of the top 10 stories and topics we ...

Alex Salmond, Janey Godley and Dame Maggie Smith are three of the famous faces from politics, comedy, showbusiness and beyond who died in 2024, remembered in part two of a double tribute ...

Jimmy Carter, Shannen Doherty and Donald Sutherland were among the notable names in media, entertainment and politics we lost ...

An enzyme called MICAL2 promotes tumor growth and metastasis in the most common form of pancreatic cancer, according to a new study.

Pancreatic cancer kills 50,000 people each year, according to the National Cancer Institute, and there are few effective ...

Pancreatic cancer is one of the most lethal malignancies, with nearly 50,000 deaths annually in the United States, according ...

Researchers at UC San Diego have discovered that the enzyme MICAL2 accelerates tumor growth in pancreatic cancer by ...